全文获取类型
收费全文 | 4792篇 |
免费 | 367篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 189篇 |
妇产科学 | 7篇 |
基础医学 | 274篇 |
口腔科学 | 17篇 |
临床医学 | 154篇 |
内科学 | 3394篇 |
皮肤病学 | 64篇 |
神经病学 | 30篇 |
特种医学 | 22篇 |
外科学 | 31篇 |
综合类 | 77篇 |
预防医学 | 53篇 |
眼科学 | 14篇 |
药学 | 158篇 |
中国医学 | 11篇 |
肿瘤学 | 680篇 |
出版年
2023年 | 90篇 |
2022年 | 24篇 |
2021年 | 54篇 |
2020年 | 138篇 |
2019年 | 133篇 |
2018年 | 123篇 |
2017年 | 127篇 |
2016年 | 153篇 |
2015年 | 152篇 |
2014年 | 185篇 |
2013年 | 243篇 |
2012年 | 154篇 |
2011年 | 192篇 |
2010年 | 178篇 |
2009年 | 192篇 |
2008年 | 187篇 |
2007年 | 210篇 |
2006年 | 160篇 |
2005年 | 170篇 |
2004年 | 147篇 |
2003年 | 170篇 |
2002年 | 181篇 |
2001年 | 167篇 |
2000年 | 173篇 |
1999年 | 119篇 |
1998年 | 116篇 |
1997年 | 136篇 |
1996年 | 143篇 |
1995年 | 138篇 |
1994年 | 106篇 |
1993年 | 43篇 |
1992年 | 44篇 |
1991年 | 46篇 |
1990年 | 35篇 |
1989年 | 33篇 |
1988年 | 36篇 |
1987年 | 36篇 |
1986年 | 20篇 |
1985年 | 80篇 |
1984年 | 32篇 |
1983年 | 30篇 |
1982年 | 37篇 |
1981年 | 46篇 |
1980年 | 32篇 |
1979年 | 42篇 |
1978年 | 37篇 |
1977年 | 31篇 |
1976年 | 19篇 |
1975年 | 17篇 |
1971年 | 4篇 |
排序方式: 共有5177条查询结果,搜索用时 31 毫秒
61.
《Annals of medicine》2013,45(7):451-455
Imatinib mesylate, also known as ST1571 or CGP57148, is a competitive inhibitor of a few tyrosine kinases, including BCR-ABL, ABL, KIT, and the platelet-derived growth factor receptors (PDGF-R). It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates. At oral doses of 300 mg or greater, the vast majority of patients with chronic myeloid leukaemia achieve a haematological response and this is usually associated with limited toxicity. Imatinib also has substantial activity in Philadelphia chromosome-positive acute lymphoblastic leukaemia expressing the BCR-ABL fusion protein. Gastrointestinal stromal tumours (GISTS) have also been evaluated for clinical activity of imatinib. About 90% of malignant GISTs harbour a mutation in c-kit leading to KIT receptor autophosphorylation and ligand-independent activation. According to initial clinical studies, more than 50% of GISTs respond to therapy within a few months, and only about 10-15% progress. The potential for cure and the optimal length of treatment are currently not known. Several other human cancers may over-express KIT or PDGF-R, and clinical trials to evaluate the role of imatinib in the treatment of such cancers are currently ongoing. Imatinib is an example of a specifically designed, highly targeted cancer therapy, which poses novel requirements for both pathology laboratories and clinicians in terms of identifying the major molecular mechanisms involved in tumour growth. 相似文献
62.
63.
64.
The hypereosinophilic syndromes (HES) encompass a spectrum of diseases that have increased blood eosinophils and tissue damage in common. The clinical manifestations are protean and may involve any organ system, but especially the skin. Our understanding of these diseases has drastically changed over the past 15 years, along with new classifications that characterize patients with marked eosinophilia. One HES variant, myeloproliferative, is actually chronic eosinophilic leukaemia with a unique genetic marker, FIP1L1-PDGFRA . Such patients are well-controlled by administration of the kinase inhibitor, imatinib, and remissions appear durable with continued imatinib therapy. FIP1L1-PDGFRA is expressed in several cell lineages, thus explaining increases in neutrophils and mast cells in HES. The lymphocytic HES variant is associated with T-cell clones producing interleukin-5 (IL-5) and can evolve into lymphoma. While myeloproliferative and lymphocytic HES are well established and permit elimination of the term, idiopathic, to these varieties, most HES patients do not fall into these categories and are classified as complex (using the 2006 Workshop Report). A recent study showed that a monoclonal antibody to IL-5, mepolizumab, reduced glucocorticoid therapy in HES patients who did not possess the FIP1L1-PDGFRA mutation while controlling eosinophilia and preventing recurrence or progression of tissue damage. These advances augur well for continued progress in the understanding and treatment of HES. 相似文献
65.
66.
Nakao M Horiike S Fukushima-Nakase Y Nishimura M Fujita Y Taniwaki M Okuda T 《British journal of haematology》2004,125(6):709-719
67.
Kensuke Kojima Takashi Sawada Masaki Yasukawa Yoshinubu Matsuo Yoshihiro Yakushijin Hiroshi Narumi Taichi Azuma Hidetaka Takimoto & Masamichi Hara 《British journal of haematology》1998,100(3):567-570
We describe the first case of T-cell prolymphocytic leukaemia (T-PLL) in which the peripheral blood cells contained a human T-lymphotropic virus (HTLV) related tax sequence. Serum screening tests for anti-HTLV-I/II antibodies were negative. Polymerase chain reaction disclosed the presence of an HTLV-I tax sequence in the peripheral blood. Other sets of oligonucleotide primers for HTLV-I gag , pol , env and the long terminal repeat regions and for the HTLV-II pol region were negative in the DNA of the cells. Although patients with T-PLL have been reported to be seronegative for HTLV-I, our findings point to the possibility that HTLV-I infection might be involved in the aetiology of at least some cases of T-PLL and that there may be alternative mechanisms involved in HTLV-associated leukaemogenesis. 相似文献
68.
Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry 总被引:5,自引:0,他引:5
Nahla Farahat Alison Morilla Kwasi Owusu-Ankomah Ricardo Morilla C. Ross Pinkerton Jennie G. Treleaven Estella Matutes Ray L. Powles & Daniel Catovsky 《British journal of haematology》1998,101(1):158-164
The clinical significance of detecting minimal residual disease (MRD) in B-lineage acute lymphoblastic leukaemia (ALL) was evaluated by quantitative flow cytometry using a combination of TdT with CD10 and CD19. 53 patients with B-cell precursor ALL were followed during and after completion of treatment (median follow-up 23 months). Nine patients relapsed and MRD had been detected in six of them, 5–15 weeks before relapse despite morphological complete remission. 43 patients remain in clinical remission and in none of these was MRD detected. Disease-free survival based on the detection of MRD by flow cytometry showed a statistically significant difference between both groups ( P < 0.0001). The absence of MRD correlates with a low relapse rate, whereas the presence of MRD predicted early relapse. This study has shown that flow cytometry can improve the morphologic assessment of bone marrow (BM) remission status in B-lineage ALL. The finding of < 5% blasts in BM aspirates did not correlate with 'true' remission in a proportion of cases as residual leukaemic blasts were detected by flow cytometry in nine samples from six patients. On the other hand, the presence of > 5% blasts assessed by morphology was not necessarily a feature of relapse in five patients as these cells were shown to have a phenotype identical to normal TdT-negative B-cell precursors. Quantitative flow cytometry was more informative than conventional morphology to assess remission status and showed a strong correlation with clinical outcome. This methodology is useful to define MRD in the majority of patients with B-lineage ALL and should be tested in prospective clinical trials. 相似文献
69.
Tohru Izumi Kazuo Muroi Masa-AKI Takatoku Shigehiko Imagawa Kiyohiko Hatake Yasusanda Miura 《British journal of haematology》1994,88(3):666-666
Summary. We report a case of aplastic anaemia (AA) treated with granulocyte colony-stimulating factor (G-CSF) terminating as acute myeloblastic leukaemia (AML). Because of severe pneumonia, 250 μg of G-CSF was administered for 30d to promote neutrophil recovery. Following G-CSF therapy, myeoblasts appeared, and the diagnosis of AML was then made. The myeloblasts proliferated in response to G-CSF in vitro and in vivo. In AA. development of AML, after treatment with G-CSF is rate. Therefore a careful observation for leukaemic transformation is necessary in long-term administration of G-CSF for AA. 相似文献
70.
Latagliata R Breccia M Fazi P Iacobelli S Martinelli G Di Raimondo F Sborgia M Fabbiano F Pirrotta MT Zaccaria A Amadori S Caramatti C Falzetti F Candoni A Mattei D Morselli M Alimena G Vignetti M Baccarani M Mandelli F 《British journal of haematology》2008,143(5):681-689
This randomized phase III clinical trial explored the efficacy of DaunoXome (DNX) versus Daunorubicin (DNR) in acute myeloid leukaemia (AML) patients aged >60 years. Three hundred and one AML patients were randomized to receive DNR (45 mg/m(2) days 1-3) or DNX (80 mg/m(2) days 1-3) plus cytarabine (AraC; 100 mg/m(2) days 1-7). Patients in complete remission (CR) received a course of the same drugs as consolidation and then were randomized for maintenance with AraC+ all trans retinoic acid or no further treatment. Among 153 patients in the DNR arm, 78 (51.0%) achieved CR, 55 (35.9%) were resistant and 20 (13.1%) died during induction. Among 148 patients in the DNX arm, 73 (49.3%) achieved CR, 47 (31.8%) were resistant and 28 (18.9%) died during induction. Univariate analysis showed no difference as to induction results. After CR, DNX showed a higher incidence of early deaths (12.5% vs. 2.6% at 6 months, P = 0.053) but a lower incidence of relapse beyond 6 months (59% vs. 78% at 24 months, P = 0.064), with a cross in overall survival (OS) and disease-free survival (DFS) curves and a later advantage for DNX arm after 12 months from diagnosis. DNX seems to improve OS and DFS in the long-term follow-up, because of a reduction in late relapses. 相似文献